WACKER’s 2025 Loss Reaches €805 Million as the PACE Cost-Cutting Plan Becomes the Key Variable for 2026

 WACKER, the German specialty chemicals group, recently released its results for fiscal 2025. The company reported full-year sales of €5.49 billion, down 4% year on year. EBITDA under the reported figure came in at €427 million, down 43%; excluding special items, EBITDA was €529 million. Full-year net loss reached €804.9 million, compared with net profit of €260.7 million a year earlier. Due to restructuring costs and asset write-downs, WACKER also announced that it would not propose a dividend for 2025. These numbers state the current reality facing European chemical companies very clearly: the market has not truly recovered, both prices and volumes remain under pressure, and the cost problem in high-energy regions has not disappeared. Even a leading specialty chemicals company cannot simply rely on “moving upscale” to pass through the cycle automatically.

If one looks only at the surface, this set of results can easily be summed up as “falling revenue, collapsing profit, direct losses.” But the explanation given by WACKER itself breaks the issue down quite clearly. In its annual report and earnings briefing, the company said that the weak performance in 2025 was not due only to soft demand. It also reflected lower product prices, reduced sales volumes, low plant utilization rates, and persistently high energy costs in Germany. Put together, these factors mean WACKER’s pressure is not coming from a single point, but from a typical multi-layer squeeze: it sold less, it sold at lower prices, its plants did not run at optimal utilization, and the region in which it operates no longer offers a clear cost advantage. For European chemical companies, this kind of situation is harder to deal with than a simple demand slowdown, because it is not something that automatically repairs itself once orders return.

What deserves even more attention is that WACKER’s 2025 loss did not come entirely from deterioration in day-to-day operations. The company clearly stated that restructuring charges and valuation adjustments were the key reasons why the full-year result turned negative. In other words, a substantial part of the €805 million loss does not mean “today’s business immediately lost that much money,” but rather that the company chose, during this low point in the cycle, to recognize the pressure it needed to recognize and deal with burdens it needed to deal with in advance. The signal behind that move is actually quite clear: WACKER is no longer planning to simply drag itself through the difficult phase, but is beginning to exchange “an ugly income statement today” for “a lighter structure over the next few years.” For the capital market, that obviously does not look good. But from an operating perspective, it often means management has shifted from “waiting for the market to improve” to “fixing the company first.”

That is why the real point to watch in this report is not just the loss itself, but the PACE program that WACKER is pushing forward at the same time. The program was launched in October 2025, with savings targets clarified further in November. Its core is a much deeper cost reduction effort across both the production system and the administrative structure, with a target of more than €300 million in recurring annual savings in the future. In its latest March 2026 statement, WACKER said implementation of PACE is proceeding according to plan. Put simply, the company is no longer satisfied with shaving off a little through minor adjustments. It wants to use structural cost reduction to change the entire earnings base. For a company with sales below €6 billion, a yearly savings target of €300 million is not a marginal number. It is a figure large enough to directly reshape profit elasticity.

From that angle, WACKER in 2025 looks very much like a company in the middle of a “profit-and-loss reset.” The old profit structure no longer works, so while it openly acknowledges that the external environment remains difficult, it is also putting more of its chips on cost restructuring and business reorganization. The guidance WACKER has given for 2026 is also very representative. The company expects low-single-digit sales growth and EBITDA in a range of €550 million to €700 million. This guidance is not aggressive; if anything, it is fairly restrained. But precisely because it is restrained, it says a great deal about WACKER’s current judgment. It is not telling the market that “the industry is about to turn sharply upward.” It is saying: the external environment is still difficult, but if costs come down and some businesses recover a bit, the company should at least perform better than it did in 2025. That is already noticeably different from the way many chemical companies in past years preferred to talk about “an inflection point in demand.”

So why is WACKER still willing to talk about “slight growth” in 2026? The key lies in its business structure. WACKER is not a typical commodity chemicals company. Its portfolio includes silicones, polysilicon, polymers, and biotechnology businesses. In its 2026 outlook, the company explicitly pointed to polysilicon and biosolutions as growth drivers, while expecting its chemicals business overall to remain roughly flat, though negatively affected by exchange rates. This indicates that WACKER is not expecting every business line to rebound at once. Instead, it is relying on a handful of relatively more resilient segments to lift the overall picture. For a specialty chemicals company, that approach is actually more realistic than hoping for “broad-based recovery.” Real recovery in this sector usually does not start with everything rising together. It begins with a few product lines and a few applications regaining strength first.

What is especially worth noting here is the real meaning behind the phrase “high-end markets.” Many companies like to say they are moving upmarket when the cycle turns down, but WACKER’s current position shows that moving upmarket is not a slogan. It requires clear business lines that can actually carry the strategy. Its polysilicon business is deeply linked to photovoltaics and semiconductors. Its biosolutions business is closer to pharmaceuticals, biotech manufacturing, and other relatively higher-value areas. In other words, WACKER’s strategic shift is not some abstract move from “low-end” to “high-end.” It is a concrete reallocation of limited resources toward segments that are better able to withstand cyclical volatility. The problem is that although these businesses have better profit quality, they are unlikely to pull the whole group sharply upward in the short term. So any recovery in 2026 is more likely to be corrective than explosive.

If the perspective is widened further, WACKER’s report also looks very much like a snapshot of the broader European chemical industry. It is not a case of lacking technology, lacking high-end products, or lacking global customers. The issue is that the cost environment, low utilization rates, and weak demand are all compressing margins at the same time. In its earnings commentary, WACKER directly highlighted the issue of high energy costs in Germany. That point is especially sensitive, because in the global chemical industry, European companies have long relied on technology, quality, and integrated systems. But when energy, labor, and regulatory costs remain structurally high, those advantages do not automatically convert into profits. WACKER’s sharp earnings deterioration in 2025 is, to a certain extent, a financial expression of that broader reality.

That is precisely why the PACE program matters so much. It is not merely there to cosmetically improve the next earnings report. It is trying to answer a more practical question: if the external environment for European chemicals is not going to improve meaningfully in the short term, what can companies still rely on to survive? WACKER’s answer is straightforward. It is not betting on a sudden surge in demand, but on acting first on production costs, fixed costs, and administrative costs. Tighten the organization, improve plant efficiency, and deal with the parts of the business that are not earning enough. Then use the relatively more resilient businesses to build the next stage of recovery. Put more plainly, whether WACKER improves in 2026 depends not only on whether the market cooperates, but on whether PACE can turn “theoretical savings” into “numbers on the profit statement.”

From the capital-market perspective, suspending the dividend is obviously a negative signal, but it also makes the company’s priorities very clear: protect cash first, protect the balance sheet first, and stabilize the operating base first. For a chemical company whose cycle has not yet clearly turned, that choice is not unusual. What really matters is whether WACKER stops at “cutting the dividend,” or whether it can connect that move to meaningful cost reductions, sharper business focus, and actual earnings repair. If the story is only losses, write-downs, and no dividend, then it is simply passive stress. If, however, the company can gradually deliver on €300 million in annual savings, then it becomes a more active adjustment story.

So how should one view WACKER’s 2025 report? The key is not to label it simply as “bad” or as “the turnaround has arrived.” A more accurate way to put it is this: 2025 was the year in which WACKER chose to expose its problems all at once, and 2026 will be the year in which the effectiveness of its adjustments is tested. Sales fell, profit turned negative, and the dividend was suspended. All of that shows the pressure is real. But at the same time, PACE is moving ahead, the savings target has been clearly defined, and the company has already guided to a modest recovery in 2026. That means WACKER is not merely standing still waiting for the cycle to turn. It is trying to repair the business in a more practical way. In the current global chemical industry, that path may be more representative than simply waiting for the market to improve on its own.